reason report
minim exposur rebat retail margin still face pressur
pt
bottom line follow call remain posit
encourag good perform quarter increas
guidanc increas adjust ep
estim slightli account quarter ep
stand call manag highlight total
retain worth rebat annual
ep medicar rebat pass-through pbm sell
season slower previou year omnicar continu
drag retail margin oper incom guidanc
enterpris retail pbm unchang midpoint
encourag impress growth retail ss rx volum
howev remain disappoint retail margin guid
maintain op rate though pt declin
care offer extend reach quest creat new
front door healthcar earn wednesday morn
announc partnership teladoc nr allow
virtual well visit minor ill injuri non-acut
need link offer allow connect patient
board-certifi provid mobil devic test
phase report satisfact level encourag
continu shift lower cost site view virtual offer
allow captur associ prescript volum
addit minut clinic volum patient need seen
person follow virtual visit offer current cost
believ reason soon insur coverag
avail current state nationwid roll-out expect
pbm sell season slow encourag pbm segment
beat oper incom estim quarter manag highlight
higher mix specialti claim claim volum increas brand
inflat driver quarter despit post good result
disappoint outlook call oper incom
growth flat low-singl digit compar previou
see fewer rfp opportun sell
season prior year report gross win net new
win complet client renew
client retent increas slightli rel previou year
net debt total capit
compani inform leerink partner llc research
revenu billion
adjust ep exclud acquisit amort one-tim item exclud interest expens relat aet transact exclud
revenu earn aet deal
pleas refer page import disclosur price chart analyst certif
retail continu turnaround long-term guid remain
tepid perform retail quarter show improv
view adj oper incom beat model ss
adjust rx volum increas impress y/i total compstore
increas y/i segment driven adopt patient
program good rx volum growth prefer posit
medicar part network market share grew bp q/q
though perform segment good past two
quarter segment revenu guidanc increas
still expect segment oper
incom declin low singl digit year continu rx growth
good disappoint continu rebound lead
earn long-term care busi weigh
result put new leadership team omnicar pursu
sever initi increas retent rate
drug price fact disclos assuag fear rebat
reinforc valu provid pbm amid continu scrutini
drug price rebat captur pbm made signific
disclosur use rebat anticip quell mani
concern disclos rebat captur
return client across book busi re-affirmed
medicar plan rebat pass
intend retain total rebat
adj ep addit current provid pos rebat
commerci member reduc out-of-pocket cost
describ pbm contract underwritten level profit
rebat serv one mani lever ensur
fair compens servic provid point drug price
growth last year highlight valu provid
client call manag also highlight recent
announc link allow use pbm tool part bring
negoti price lower price part program
evid value-prop pbm provid continu believ
pbm offer valuabl servic consist aim
slightli post two quarter adj ep beat start
manag rais midpoint guidanc
compar prior leerink/consensu
revenu guidanc reduc slightli midpoint
consolid adj oper profit growth guidanc
narrow
encourag increas adj ep guid
view offset slightli weaker expect adj ep guidanc
exclud aet mp interest expens slightli
behind prior leerink/consensu
tweak estim given adj ep beat
increas midpoint guid increas full year
estim overal view quarter good
beat come pbm perform lower tax lower interest
expens rel model maintain op rate pt
declin
believ stand benefit brand gener convers pbm share gain growth
retail high growth rate specialti pharmaceut retail pharmaci
pbm believ differenti offer substanti buy power allow
compani price highli competit deliv high qualiti care uniqu cost
save model mani plan sponsor seek narrow network consid one
best market -- preval expect increas next
year estim alreadi one largest retail chain countri expect
addit growth come open new pharmaci acquisit
independ pharmaci smaller chain next sever year expect gener
drug launch advent biosimilar remain industri trend help drive
margin expans believ minuteclin benefit grow emphasi
popul health manag expect see increment benefit sell
season express script esrx optum continu streamlin oper
integr new custom win acquisit also posit propos cvs/aet
combin deal enabl live integr medic pharmaci
benefit aet live creat new sourc revenu earn
next month expect share trade ep
would put stock price target believ deserv trade
slight discount histor multipl given slowdown gener launch calendar
on-going challeng environ restrict narrow network howev pick
gross win pbm sell season reflect strength core
busi model furthermor lap lost rx headwind retail top-lin
growth re-acceler believ well posit take advantag growth
gener specialti pharmaceut believ retail pbm valu proposit
mainten choic offer reson well market believ
continu win pbm share also help drive volum retail store
competit high chang retail pharmaci pbm market highli
competit industri consolid chang retail pbm landscap
acquisit medco express script merger health solut catalyst
health solut walgreen allianc boot combin
consolid market share among largest compani pbm may need price
aggress retain custom impact profit custom retent
macroeconom climat uncertain continu econom slowdown would bode
poorli client individu consum retail pharmaci product pbm plan
sponsor would suffer averag unemploy rate along averag level
consum spend purchas power would decreas prescript drug util weak
macroeconom outlook would also hurt profit pbm client possibl decreas
number cover live
organ govern entiti third-parti seek decreas prescript
drug cost seek increas substitut gener drug brand drug
normal benefici bottom line retail pharmaci downward pressur
reimburs rate pharmaci could start cut away margin consolid among
gener pharmaceut manufactur may squeez pharmaci would difficult
negoti reduc acquisit cost strong focu feder state govern
rein healthcar cost healthcar financ reimburs rate subject chang
variou polit econom interest exert influenc regulatori environ
failur retain/win new pbm contact pbm contract provid healthcar servic plan
member typic durat three year mean pbm client base
renew given year inher risk exist abil retain contract
renew also certain pbm client may tailor contract deviat typic term
may renegoti contract prior expir
medicar part regul risk particip medicar part prescript
drug program retail pharmaci realiz increas drug util compress
margin individu migrat higher margin plan one howev medicar
part busi could impact one sever factor includ chang drug cost
retire drug subsidi revis medicar program requir reduct fund failur
integr acquir medicar part busi failur win new contract
transact risk risk cvs/aet transact either wont close due
regulatori constraint integr deal may prove challeng
expect also risk invest commun sentiment transact
combin segment revenu
incom statement model fiscal year end decemb mm
pharmaci retail
good sold
revenu
revenu
earn alloc particip secur
net loss attribut non-control interest
adjust incom continu oper
adjust one-tim item
adj incom cont op ex amort
adjust dilut ep ex amort
incom statement model fiscal year end decemb mm
net incom continu oper
net loss attribut non-control interest
prefer dividend net incom tax benefit
net incom attibut caremark
cog net revenu
oper expens net revenu
depreci amort
 total
incom statement model fiscal year end decemb mm
cog net revenu
oper expens net revenu
depreci amort
pharmaci total revenu
third parti pharmaci revenu
depreci amort
combin revenu
depreci amort
